NERV Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
9.4M
-11.4%
10.6M
-36.2%
16.7M
+234.7%
5.0M
+75.1%
2.8M
R&D
5.2M
-28.3%
7.2M
+36.8%
5.3M
+141.8%
2.2M
+134.9%
925.4K
SG&A
4.3M
+23.8%
3.5M
-69.7%
11.4M
+306.6%
2.8M
+46.3%
1.9M
Operating Income
-9433677
+11.4%
-10642159
+36.2%
-16671552
-234.7%
-4981589
-75.1%
-2844348
EBITDA
-9433677
+11.4%
-10642159
+36.2%
-16671552
-234.8%
-4980229
-75.2%
-2842987
Net Income
100.7M
+476.8%
17.5M
+113.9%
-125404384
+55.8%
-283667663
-10237.9%
-2743954
EPS (Basic)
$1.94
+438.9%
$0.36
+112.6%
$-2.86
+88.8%
$-25.45
-6969.4%
$-0.36
EPS (Diluted)
$-0.19
-35.7%
$-0.14
+95.1%
$-2.86
+88.8%
$-25.45
-6969.4%
$-0.36
Shares (Diluted)
75.3M
-4.9%
79.1M
+80.2%
43.9M
+293.8%
11.1M
+47.3%
7.6M
Minerva Neurosciences (NERV) — Financials